Vanda Pharmaceuticals Inc. $VNDA Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lowered its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,922 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the period. Public Employees Retirement System of Ohio owned about 0.06% of Vanda Pharmaceuticals worth $155,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $2,022,000. GSA Capital Partners LLP increased its position in shares of Vanda Pharmaceuticals by 88.0% during the first quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock worth $1,194,000 after purchasing an additional 121,797 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $875,000. XTX Topco Ltd increased its position in shares of Vanda Pharmaceuticals by 378.3% during the first quarter. XTX Topco Ltd now owns 69,329 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 54,833 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Vanda Pharmaceuticals by 13.5% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company’s stock worth $4,267,000 after purchasing an additional 110,262 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Saturday, September 27th. Finally, Wall Street Zen lowered Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $16.50.

Vanda Pharmaceuticals Stock Down 0.6%

NASDAQ VNDA opened at $5.40 on Tuesday. Vanda Pharmaceuticals Inc. has a 52-week low of $3.81 and a 52-week high of $5.55. The business’s 50-day moving average price is $4.61 and its 200 day moving average price is $4.53. The firm has a market cap of $319.09 million, a P/E ratio of -4.78 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The company had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.